conducted a retrospective analysis of the efficacy and safety of PD-1 inhibitors plus anlotinib in patients with advanced non-small cell lung cancer after failure of previous systemic therapy (60), which also showed anti-tumor activity and tolerable adverse effects of immune checkpoint inhibitors in combination with anti-angiogenic agents. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.